• 1
    Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1997; 83: 1829.
  • 2
    IARC. Human papillomavirus. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC, 1995. 64.
  • 3
    Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 341: 16338.
  • 4
    Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995; 76: 1888901.
  • 5
    Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. Hum Reprod Update 1999; 5: 43347.
  • 6
    Bjartling C, Osser S, Persson K. The frequency of salpingitis and ectopic pregnancy as epidemiologic markers of Chlamydia trachomatis. Acta Obstet Gynecol Scand 2000; 79: 1238.
  • 7
    Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327: 12728.
  • 8
    Munoz N, Bosch FX, de Sanjose S, Vergara A, de moral A, Munoz MT, Tafur L, Gili M, Izarzugaza I, Viladiu P, Navarro C, Alonso de Ruiz P, et al. Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993; 2: 42331.
  • 9
    Hakama M, Lehtinen M, Knekt P, Aromaa A, Leinikki P, Miettinen A, Paavonen J, Peto R, Teppo L. Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. Am J Epidemiol 1993; 137: 16670.
  • 10
    de Sanjose S, Munoz N, Bosch FX, Reimann K, Pedersen NS, Orfila J, Ascunce N, Gonzalez LC, Tafur L, Gili M, Lette I, Viladiu P, et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 1994; 56: 35863.
  • 11
    Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, Jellum E, Lehtinen M, Lenner P, Hakulinen T, Narvanen A, Pukkala E, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. J Am Med Assoc 2001; 285 (1): 4751.
  • 12
    Koskela P, Anttila T, Bjorge T, Brunsvig A, Dillner J, Hakama M, Hakulinen T, Jellum E, Lehtinen M, Lenner P, Luostarinen T, Pukkala E, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000; 85: 359.
  • 13
    Paavonen J, Vesterinen E, Meyer B, Saikku P, Suni J, Purola E, Saksela E. Genital Chlamydia trachomatis infections in patients with cervical atypia. Obstet Gynecol 1979; 54: 28991.
  • 14
    Chua KL, Hjerpe A. 1996. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996; 77: 1217.
  • 15
    Chua KL, Hjerpe A. Polymerase chain reaction analysis of human papillomavirus in archival cervical cytologic smears. Anal Quant Cytol Histol 1995; 17: 2219.
  • 16
    Vincelette J, Schirm J, Bogard M, Bourgault AM, Luijt DS, Bianchi A, van Voorst Vader PC, Butcher A, Rosenstrauss M. Multicenter evaluation of the fully automated COBAS AMPLICOR PCR test for detection of Chlamydia trachomatis in urogenital specimens. J Clin Microbiol 1999; 37: 7480.
  • 17
    Hirji KF, Tsiatis AA, Mehta CR. Median unbiased estimation for binary data. Am Statist 1989; 43; 711.
  • 18
    Ylitalo N, Josefsson A, Melbye M, Sorensen P, Frisch M, Andersen PK, Sparen P, Gustafsson M, Magnusson P, Ponten J, Gyllensten U, Adami HO. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60 (21): 602732.
  • 19
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 129.
  • 20
    Mitao M, Reumann W, Winkler B, Richart RM, Fujiwara A, Crum CP. Chlamydial cervicitis and cervical intraepithelial neoplasia: an immunohistochemical analysis. Gynecol Oncol 1984; 19: 907.
  • 21
    Kiviat NB, Peterson M, Kinney-Thomas E, Tam M, Stamm WE, Holmes KK. Cytologic manifestations of cervical and vaginal infections. II. Confirmation of Chlamydia trachomatis infection by direct immunofluorescence using monoclonal antibodies. J Am Med Assoc 1985; 15; 253 (7): 9971000.
  • 22
    Lehmann M, Groh A, Rodel J, Nindl I, Straube E. Detection of Chlamydia trachomatis DNA in cervical samples with regard to infection by human papillomavirus. J Infect 1999; 38: 127.
  • 23
    Quinlivan JA, Petersen RW, Gurrin LC. High prevalence of chlamydia and Pap-smear abnormalities in pregnant adolescents warrants routine screening. Aust N Z J Obstet Gynaecol 1998; 38: 2547.
  • 24
    Dillner J, Lenner P, Lehtinen M, Eklund C, Heino P, Wiklund F, Hallmans G, Stendahl U. A population-based seroepidemiological study of cervical cancer. Cancer Res 1994; 54: 13441.
  • 25
    Fan T, Lu H, Hu H, Shi L, McClarty GA, Nance DM, Greenberg AH, Zhong GJ. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 1998; 187: 48796.
  • 26
    Mavoungou E, Poaty-Mavoungou V, Toure FS, Sall A, Delicat A, Yaba P, Mandeme Y, Nabias R, Lansoud-Soukate J. Impairment of natural killer cell activity in Chlamydia trachomatis infected individuals. Trop Med Int Health 1999; 4: 71927.
  • 27
    Tseng CT, Rank RG. Role of NK cells in early host response to chlamydial genital infection. Infect Immun 1998; 66: 586775.
  • 28
    Wang S, Fan Y, Brunham RC, Yang X. IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection. Eur J Immunol 1999; 29: 378292.
  • 29
    Zhong G, Fan T, Liu L. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med 1999; 189: 19318.